HDAC9 and prostate carcinoma: In prostate cancer, RVT has been demonstrated to lead to the promotion of acetylation on Lys125 and Lys128 of PTEN as well as its reactivation by inhibiting of the MTA1/HDAC complex, which results in the inactivation of the PKB pathway.